Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Sleep apnoea is common among older adults but is often overlooked or ignored leading to delayed diagnosis and treatment ...

Recognizing the symptoms of sleep apnea is crucial for early diagnosis ... A score of 5-15 is considered as mild, 15-30 as moderate and more than 30 as severe sleep apnea. Additionally, the ...

In this ar we will explore the symptoms, diagnostic tests, and treatment options available to tackle this debilitating condition. Sleep apnea occurs when there are repeated pauses or interruptions ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Mild sleep-disordered breathing occurs when children have obstructive sleep apnea symptoms but no clear obstructive sleep apnea on sleep lab testing. The Pediatric Adenotonsillectomy Trial for ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Sleep disordered breathing is a range of conditions that cause abnormal breathing during sleep, including snoring and obstructive sleep apnea ... to 15 disruptions, mild sleep problems; and ...

Sleep apnea is known to wreak havoc on the body and ... About 56% of the people had no sleep problems, compared to 28% who had mild sleep problems and 16% who had moderate to severe sleep problems.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.